h digitalfootprint web 728x90

NewLink Genetics licenses ovarian cancer drug to Ellipses Pharma


NewLink Genetics Corp. announced Monday that the company has entered into an exclusive worldwide license agreement with Ellipses Pharma Ltd. for the development of and rights to commercialize its drug compound known as NLG207, which has shown promising results in Phase 2 trials for treating ovarian cancer. Under the terms of the agreement, London-based Ellipses purchased NewLink’s inventory of NLG207-related materials, and NewLink will have the potential to receive future royalty payments or a share of any future economics related to NLG207. As part of the license agreement, Ellipses also gained the rights to develop and commercialize CRLX-301, a nanoparticle formulation of the cancer drug docetaxel that has completed a Phase 1a study. NewLink, based in Ames, is shifting its focus to the development of therapeutics for rare diseases with its planned merger with Texas-based Lumos Pharma Inc. 

Facebook Notice for EU! You need to login to view and post FB Comments!

hy vee web 030123 300x250